Menlo Therapeutics

Science Behind Serlopitant

Serlopitant, a highly selective, once-daily, oral small molecule inhibitor of the neurokinin 1 receptor, or NK₁R, is an investigational drug that acts through a novel mechanism to potentially alleviate pruritus associated with various conditions.

Leadership

Our leadership team brings together significant clinical development, regulatory, manufacturing and commercialization experience to advance serlopitant for the treatment of several conditions with significant unmet medical need.

Board of Directors

Our experienced board of directors consists of Steve Basta, Paul Berns, Ted Ebel, David McGirr, Elisabeth Sandoval and Scott M. Whitcup.

Pipeline of Indications

Development Programs at Menlo Therapeutics with Serlopitant

Newsroom